Cat. No.: HY-W783478

Calebin A

Avis client

Based on 1 Customer Validation

Calebin A is a PI3K/Akt/mTOR, MAPK, and NF-κB inhibitor with oral effectiveness. Calebin A can block the autophagy-repressive, inhibiting apoptosis. Calebin A has anti-tumor activity by epigenetic regulation. Calebin A suppresses adipogenesis, modulates thermogenesis, and enriches gut probiotics. Calebin A can be used in research on osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.0%
CAS No.: 336784-82-8
Formule: C₂₁H₂₀O₇
Masse moléculaire:384.38

Stockage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Calebin A Chemical Structure

CAS No.: 336784-82-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform PI3K :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform mTOR :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform NF-κB :

Cellular Effect

Cell Line	Type	Value	Description	References
IMR-32	ED₅₀	1.4 μg/mL Compound: 1	Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards IMR-32 human neuroblastoma cell Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards IMR-32 human neuroblastoma cell	[PMID: 11549465]
PC-12	ED₅₀	1 μg/mL Compound: 1	Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards PC12 rat pheochromocytoma cell Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards PC12 rat pheochromocytoma cell	[PMID: 11549465]
PC-12	ED₅₀	1 μg/mL Compound: 1, calebin-A	Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay	[PMID: 12350137]
PC-12	ED₅₀	2 μg/mL Compound: 1, calebin-A	Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay	[PMID: 12350137]

In Vitro

Calebin A (5 μM) suppresses apoptosis and promotes autophagic Beclin-1 expression in primary canine chondrocytes cultured in an osteoarthritis environment^[1].
Calebin A (5 μM) upregulates ECM and autophagy markers, downregulates inflammation, degradation, apoptosis, and mTOR/PI3K/Akt signaling in primary canine chondrocytes cultured in an osteoarthritis environment, with effects dependent on intact autophagy^[1].
Calebin A inhibits colonosphere formation, proliferation, invasion/migration, and enhances apoptosis in HCT116, RKO, and SW480 colorectal cancer cells via modulation of TNF-β/NF-κB signaling and associated biomarkers^[2].
Calebin A overcomes vincristine resistance, induces G₂/M-phase arrest and apoptosis in SGC7901 gastric cancer cells via modulation of MAPK signaling and P-glycoprotein^[2].
Calebin A reduces growth and viability of Sup-T1 lymphoma cells and modulates epigenetic enzymes (HAT, HDAC, PCAF)^[2].
Calebin A down-regulates inflammation in canine tenocytes via NF-κB/Scleraxis signaling^[2].
Calebin A (20 μM) suppresses adipogenesis and induces lipolysis in adipocytes, with lipolysis induced at 20 μM^[2].
Calebin A (25 μM; 24 h) induces G₂/M phase decrease and G₁ phase increase in STS26T, S462-TY, ST8814, and T265 MPNST cells, arresting cell cycle progression^[3].
Calebin A (12.5-25 μM) downregulates phosphorylated AKT, phosphorylated ERK1/2, survivin, hTERT, and acetylated histone H3 in MPNST cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

S462-TY, ST8814, T265, STS26T MPNST cell lines; LinNF primary neurofibroma cells
Concentration:

6.25, 12.5, 25, 50, 100 μM
Incubation Time:

24 h
Result:

Decreased viability of MPNST cell lines at 12.5-25 μM; reduced survival by less than 50% in all MPNST cell lines with 25 μM treatment; inhibited growth of primary neurofibroma cells.

Cell Cycle Analysis^[3]

Cell Line:

STS26T, S462-TY, ST8814, T265 MPNST cell lines
Concentration:

25 μM
Incubation Time:

24 h
Result:

Decreased STS26T cells in G2/M phase from 12.6% to 11.4% and increased G1 phase from 73.6% to 74.6%; reduced S462-TY G2/M phase from 19.7% to 8.8%, ST8814 G2/M phase from 6.4% to 6.0%, and T265 G2/M phase from 23.1% to 18.3%.

Cell Proliferation Assay^[5]

Cell Line:

HCT116 colorectal cancer cells (co-cultured with MRC-5 fibroblasts and Jurkat T-lymphocytes in multicellular proinflammatory TME; or co-cultured with MRC-5 fibroblasts and 10 ng/ml TNF-β in TNF-β-TME)
Concentration:

1-5 μM (10 days treatments); 5 μM (4 h immunofluorescence assay)
Incubation Time:

10 days (MTT, colonosphere, invasion, Western blotting); 4 h (immunofluorescence)
Result:

Dose-dependently inhibited HCT116 cell proliferation, with maximum inhibition at 5 μM. Reduced colonosphere formation and invasion dose-dependently. Decreased nuclear p65-NF-κB labeling to 21% in multicellular TME and 22% in TNF-β-TME at 5 μM after 4 h treatment. Increased apoptosis to 59% in multicellular TME and 48% in TNF-β-TME at 5 μM after 4 h treatment. Suppressed p65-NF-κB phosphorylation, NF-κB-regulated gene products (MMP-9, CXCR4, Ki-67, β1-integrin), and cancer stem cell markers (CD133, CD44, ALDH1) dose-dependently. Increased cleaved caspase-3 dose-dependently.

Parmacokinetics

Species	Dose	Route	T_1/2	CL_total	CL_renal	CL_hepatic
Rat^[6]	20 mg/kg	i.v.	3.43 μg/mL	61 L/h/kg	0.11 L/h/kg	60.9 L/h/kg
Rat^[6]	100 mg/kg	p.o.	1.18 μg/mL	11244.3 L/h/kg	0.274 L/h/kg	11244.0 L/h/kg

In Vivo

Calebin A (100 mg/kg/d; p.o.; daily; 90 days) is safe when administered orally to female and male Wistar rats for 90 days, with no observed toxicity^[2].
Calebin A (500 mg/kg; oral; single dose ) exhibits pharmacokinetic properties including ~0.5% bioavailability, 1-3 hour serum half-life, and primarily non-renal excretion in male Sprague-Dawley rats^[2].
Calebin A (100 mg/kg; i.p.; three times a week; 15 days) significantly reduces xenograft tumor size in a mouse MPNST model^[3].
Calebin A (0.1-0.5%; dietary supplementation; daily; 12 weeks) exhibits dose-dependent anti-obesity effects in high-fat diet-induced obese mice by reducing body weight and blood glucose, restoring liver weight, enhancing adaptive thermogenesis, and modulating gut microbiota composition^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c nude (male, 4 weeks old, MPNST xenograft model with S462-TY cells)^[3]
Dosage:

100 mg/kg
Administration:

i.p.; three times a week; 15 days
Result:

Significantly decreased xenograft tumor size two weeks post-treatment.

Animal Model:

C57BL/6 (male, 4 weeks old, high-fat diet-induced obesity)^[4]
Dosage:

0.1%; 0.5%
Administration:

high-fat diet (HFD) supplementation; daily; 12 weeks
Result:

Reduced body weight in a dose-dependent manner; lowered fasting blood glucose and liver weight to normal diet levels (0.5% dose); decreased weights of white, beige, and brown adipose tissues (0.5% dose); improved liver color by reducing lipid accumulation (0.5% dose); better maintained rectal temperature with a higher area under the curve for temperature change than the high-fat diet group during 4°C cold exposure (0.5% dose); reduced Firmicutes-to-Bacteroidetes ratio from 1.24 ± 0.29 to 1.03 ± 0.42 (0.5% dose); increased Verrucomicrobia phylum abundance from 0.002 ± 0.001 to 0.022 ± 0.02 (0.5% dose); enriched genera including Akkermansia, Butyricicoccus, Ruminiclostridium_9, and unidentified_Ruminococcaceae (0.5% dose).

Chemical Information

CAS No. 336784-82-8
Appearance Solid
Masse moléculaire 384.38
Formule C₂₁H₂₀O₇
Color Off-white to light yellow
SMILES

COC(C=C1/C=C/C(OCC(/C=C/C2=CC(OC)=C(C=C2)O)=O)=O)=C(C=C1)O
Structure Classification
- Phenols
- Polyphenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (260.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6016 mL

13.0080 mL

26.0159 mL

5 mM

0.5203 mL

2.6016 mL

5.2032 mL

10 mM

0.2602 mL

1.3008 mL

2.6016 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.50 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (279 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Oliveira AL, et al. Calebin A: Analytical Development for Pharmacokinetics Study, Elucidation of Pharmacological Activities and Content Analysis of Natural Health Products. J Pharm Pharm Sci. 2015;18(4):494-514. [Content Brief]

[2]. Brockmueller A, et al. Calebin A modulates inflammatory and autophagy signals for the prevention and treatment of osteoarthritis. Front Immunol. 2024;15:1363947. Published 2024 Mar 4. [Content Brief]

[3]. Brockmueller A, et al. Multifunctionality of Calebin A in inflammation, chronic diseases and cancer. Front Oncol. 2022;12:962066. Published 2022 Sep 16. [Content Brief]

[4]. Lee MJ, et al. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. Phytomedicine. 2019;57:377-384. [Content Brief]

[5]. Lee PS, et al. Calebin-A prevents HFD-induced obesity in mice by promoting thermogenesis and modulating gut microbiota. J Tradit Complement Med. 2022;13(2):119-127. Published 2022 Jan 5. [Content Brief]

[6]. Buhrmann C, et al. Multitargeting Effects of Calebin A on Malignancy of CRC Cells in Multicellular Tumor Microenvironment. Front Oncol. 2021;11:650603. Published 2021 Sep 29. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6016 mL	13.0080 mL	26.0159 mL	65.0398 mL
	5 mM	0.5203 mL	2.6016 mL	5.2032 mL	13.0080 mL
	10 mM	0.2602 mL	1.3008 mL	2.6016 mL	6.5040 mL
	15 mM	0.1734 mL	0.8672 mL	1.7344 mL	4.3360 mL
	20 mM	0.1301 mL	0.6504 mL	1.3008 mL	3.2520 mL
	25 mM	0.1041 mL	0.5203 mL	1.0406 mL	2.6016 mL
	30 mM	0.0867 mL	0.4336 mL	0.8672 mL	2.1680 mL
	40 mM	0.0650 mL	0.3252 mL	0.6504 mL	1.6260 mL
	50 mM	0.0520 mL	0.2602 mL	0.5203 mL	1.3008 mL
	60 mM	0.0434 mL	0.2168 mL	0.4336 mL	1.0840 mL
	80 mM	0.0325 mL	0.1626 mL	0.3252 mL	0.8130 mL
	100 mM	0.0260 mL	0.1301 mL	0.2602 mL	0.6504 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Calebin A

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Voir tous les produits spécifiques à Isoform PI3K

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform mTOR

Voir tous les produits spécifiques à Isoform p38 MAPK

Voir tous les produits spécifiques à Isoform NF-κB

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références